Atomera (ATOM) Q4 2020 earnings summary

Executive summary

• 2020 results reflected an early-stage licensing model: revenue was limited to integration services and licenses, while R&D and commercialization work drove continued operating losses.

• A January 2021 JDA granted a leading semiconductor provider an upfront paid manufacturing license; further milestone revenue is conditional, and the agreement grants no distribution rights.

• Year-end cash and cash equivalents rose to $37.9 million, supported by public and at-the-market equity offerings, providing funding for planned development and customer work.

Financial highlights

• FY2020 revenue was $62,000 vs. $533,000 in FY2019; gross margin was $49,000 vs. $280,000.

• Operating expenses rose to $14.969 million from $13.905 million; loss from operations was $14.920 million vs. $13.625 million.

• Net loss was $14.878 million vs. $13.300 million; basic and diluted loss per share was $0.79 vs. $0.84.

• R&D expense increased 9% to $8.424 million; G&A rose 8% to $5.624 million, while selling and marketing decreased 4% to $921,000.

Outlook and guidance

• Management expected available working capital to fund current plans and obligations for at least 12 months after filing; plans include higher R&D headcount and outsourced fabrication and testing spend.

• Commercialization depends on customer integration, qualification and licensing; the industry testing cycle can take 18–36 months or longer, with limited company control over customer schedules.

• The January 2021 JDA may generate additional revenue if development milestones are achieved; no commercial distribution license or commitment to production is included.